AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01471574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets; oral; for patients weighing \<75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing >75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
Study NCT01471574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Interferon alfa 2a
Description: Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
Study NCT01795937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: twice daily
Study NCT01795937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: single dose
Study NCT01795937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: once daily
Study NCT01795937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: single dose
Study NCT02802865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Study NCT02802865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT02802865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT01994499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videothoracoscopy drainage
Description: videothoracoscopy drainage of pleural effusion
Study NCT01994499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical drainage
Description: Medical pleural drainage
Study NCT03923478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-M201
Description: Active Treatment
Study NCT03923478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control Treatment
Study NCT02616653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L3-L4 location: Palpation method confirmed by US
Description: An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
Study NCT00583479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: one injection into the celiac ganglion
Description: one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
Study NCT00583479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: two injections into the celiac ganglion
Description: two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
Study NCT02060825 — intervention group
Intervention type: DEVICE
Intervention: Regional saturation monitor
Study NCT03206957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Funduscopic examination and retinal photography
Description: A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
Study NCT03206957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum levels of endostatin and angiogenesis factors
Description: Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
Study NCT03206957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Renal and low urinary tract Doppler ultrasound
Description: Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.~Doppler ultrasound examination will assess renal arterial resistivity indexes
Study NCT03206957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urinalysis
Description: Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
Study NCT03206957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Anthropometric measures and vitals signs
Description: weight, height and blood pressure will be assessed
Study NCT00332371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPFA (Coupled Plasma Filtration Adsorption)
Description: CPFA is a specific method for the treatment of sepsis.~It consists of:~1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~2. a hemofilter (polyethersulfone 1,4 m2)~3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter.
Study NCT01371435 — intervention group
Intervention type: DRUG
Intervention: Paroxetine
Study NCT04540939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions.
Study NCT04540939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxation Therapy
Description: Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
Study NCT03167619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Product
Description: olaparib 300mg twice daily
Study NCT03167619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Product in combination with Durvalumab
Description: olaparib 300mg twice daily plus intravenous durvalumab every 28 days
Study NCT00390923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline + nicotine replacement therapy
Description: Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
Study NCT00390923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + nicotine replacement therapy
Description: Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
Study NCT00746772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purslane 235mg/day in one dosage
Description: Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
Study NCT00746772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo : one dosage
Description: Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
Study NCT04210713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 200 mg/day
Study NCT04210713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Matched placebo
Study NCT04272307 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: At inclusion, at day 5, day 42 and at 3 months, one 2 ml EDTA blood tube will be collected for metabolomics.~Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method.~At inclusion, one 2 ml EDTA tube will be stored as a DNA collection.
Study NCT04272307 — intervention group
Intervention type: PROCEDURE
Intervention: Stool samples
Description: One stool sample will be taken at baseline, day 5, day 42 and at 3 months and frozen at -80°C and divided in 2 aliquots.~One stool aliquot will be used for metabolomics. Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method. The other one will be used for microbiota analysis. Samples will be sent to the McGill University (Prof. SALEH's lab) for extraction and then, Génome Québec Innovation Centre (McGill University, Montréal, Canada) for sequencing of the V4 region of the 16S rRNA gene on Illumina MiSeq in paired-end mode.
Study NCT04272307 — intervention group
Intervention type: PROCEDURE
Intervention: Colorectal biopsies
Description: During routine flexible sigmoidoscopy, 6 biopsies will be collected with a 5 mm biopsy forceps at baseline and at 3 months. Biopsies will be placed into a sterile vial containing RNAlater (Qiagen, Hilden, Germany) and stored at -80°C. Two biopsies will be used for mucosal microbiome analysis in the same way as the stool sample. Four biopsies will be used for RNAseq. Samples will be shipped to Prof. SALEH's lab in Montréal for nucleic acid extraction. The McGill University and Génome Québec Innovation Centre (McGill University, Montréal, Canada) will provide library preparation and next generation sequencing. The average number of uniquely mapped reads per sequencing run will be 30 million reads per sample.
Study NCT03115645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Work
Description: The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
Study NCT03618225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Duloxetine 60mg
Description: duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
Study NCT03618225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
Study NCT02887144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
Study NCT05327777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Investigators provided set opioid prescriptions for 10 pills each patient.
Study NCT05327777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero Opioid Protocol
Description: Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
Study NCT03881943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60 mg
Description: Potent antiplatelet agent, 60mg twice daily for 3 months
Study NCT03881943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 MG Oral Tablet, Enteric Coated
Description: antiplatelet agent, 100mg once daily for 3 months
Study NCT00151593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celsior®
Description: Graft preservation solution
Study NCT03276559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment.
Study NCT03276559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
Study NCT00091377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
Study NCT00091377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
Study NCT00091377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenoxodiol
Description: IV 3 mg/kg
Study NCT04122950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
Study NCT00402103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
Study NCT00773383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: iv 9mg/kg weekly
Study NCT00773383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg oral daily
Study NCT00402103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
Study NCT02935374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
Study NCT02935374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate
Description: The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
Study NCT02992431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory patient care planning
Description: Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
Study NCT02992431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care including standard disease specific follow-up with visit to general practitioner.
Study NCT02887144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura test product
Description: SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
Study NCT01601015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
Study NCT00402103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
Study NCT01701323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
Description: Given IV
Study NCT01701323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02163447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Study NCT01701323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV
Study NCT01701323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04801654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
Study NCT01447147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules once daily
Study NCT02163447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Study NCT02163447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
Study NCT01635582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hand exercise program
Description: Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
Study NCT01635582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer gaming hand exercise regimen
Description: Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
Study NCT03595462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack
Description: Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be \~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be \~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat.
Study NCT01447147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group B)